retatrutide clinical trials retatrutide Subcutaneous Fat Loss Results: What Reveal About Effectiveness and Safety RETATRUTIDE (RETA)

Weight loss : Retatrutide showed 28.7% at 68 weeks (Phase 3 TRIUMPH-4) versus survodutide's 18.7% at 46 weeks (Phase 2), though cross-trial comparisons are inherently limited

Request a consultation and lets talk about what might work best for you

The glucagon receptor arm the feature that distinguishes retatrutide from earlier-generation incretin compounds drives hepatic glucose metabolism, lipid oxidation, and energy expenditure effects, all absent from GLP-1 mono-agonists and dual GLP-1/GIP agonists

Our manufacturing process follows GMP standards so researchers can get consistently high quality material for their research

Pause halfway through and check in

Microdosing GLP-1 means using doses significantly below the approved therapeutic range, but this practice lacks clinical trial evidence and is not approved by the MHRA